Literature DB >> 29468637

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.

Toby A Eyre1, Christopher P Fox2, Ali Boden3, Adrian Bloor4, Moez Dungawalla5, Paneesha Shankara6, Richard Went7, Anna H Schuh1,8.   

Abstract

Entities:  

Keywords:  B-PLL; TP53 deletion, TP53; idelalisib; prolymphocytic leukaemia

Year:  2018        PMID： 29468637     DOI： 10.1111/bjh.15151

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  Relapsed disease and aspects of undetectable MRD and treatment discontinuation.

Authors:  Barbara Eichhorst; Moritz Fürstenau; Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 2.  How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.

Authors:  José Cabeçadas; Victor E Nava; Joao L Ascensao; Maria Gomes da Silva
Journal:  Curr Oncol       Date:  2021-11-11       Impact factor: 3.677

3.  Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax.

Authors:  Maria Tariq Siddiqui; Allyson Price; Alessandra Ferrajoli; Gautam Borthakur
Journal:  Leuk Res Rep       Date:  2021-08-30

Review 4.  Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review.

Authors:  Lijie Xing; Qiang He; Linna Xie; Hui Wang; Zengjun Li
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 9.941

5.  A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).

Authors:  Toby A Eyre; Gavin Preston; Huseini Kagdi; Amin Islam; Toby Nicholson; Harry W Smith; Adam P Cursley; Heribert Ramroth; Guan Xing; Lin Gu; Nishanthan Rajakumaraswamy; Christopher Fegan
Journal:  Br J Haematol       Date:  2021-06-14       Impact factor: 6.998
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.